Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Bioray Laboratories
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05381181CT.gov Safety and Efficacy Evaluation of Next-generation CD19-UCART | — | Unknown | — | — | — |
NCT05098613CT.gov Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | — | Recruiting | — | — | — |
NCT05206071CT.gov Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT03229876CT.gov Safety and Efficacy Evaluation of CD19-UCART | — | Suspended | — | — | — |
NCT04237428CT.gov CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma | — | Unknown | — | — | — |
NCT03448393CT.gov CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd19-ucart (this asset) | Bioray Laboratories | P1 | CC · 42 |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
| (+)-Vincristine | Mwanasha Merrill, MD | P3 | BB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for cd19-ucart
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 71 |
| Acute Lymphoblastic Leukemia | — | P2 | B · 63 |
| B-Cell Acute Lymphoblastic Leukemia | — | P2 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd19-ucart in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd19-ucart-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →